What happens to your clients when you sell?

This is the question most owners actually lose sleep over, and it is the one the sale literature answers least well — because most of it is written by people who have never carried a caseload.

The short version is reassuring and then complicated. Reassuring because in a well-run transition most clients experience very little. Complicated because the things that protect them are not the things the deal is optimising for, and somebody has to hold that line deliberately.

What usually changes for a client, and what does not

In the ordinary case — a group practice sold to another group or a platform, with the clinical team staying — a client keeps the same therapist, the same appointment time and the same room. What changes sits behind them: who owns the entity, whose name is on the paperwork, sometimes the billing system, sometimes the branding.

That is the case worth aiming for, and it is also the case a buyer wants. Which brings up the thing owners rarely realise they have on their side.

The buyer’s interest and your clients’ interest mostly agree

A buyer is purchasing continuing revenue. Every client who leaves during a transition is value they paid for and did not receive, and every clinician who leaves takes a caseload with them.

So when you argue for a careful, unhurried, clinically-led transition, you are not asking the buyer for a favour against their interests. You are describing the thing they are trying to buy. Owners often approach this conversation braced for a fight and find the buyer already agrees — the pressure usually comes from the timeline, not from anyone’s indifference.

Where the interests genuinely diverge is speed. Diligence and closing run on a deal clock. Clinical transitions do not, and cannot be made to.

The real risk is clinician turnover, not the sale itself

Clients do not usually leave because ownership changed. They leave because their therapist did.

That is why the same preparation that raises your price also protects your clients: signed clinician agreements, a team with real tenure, a clinical director who is not you. A practice whose clinicians stay is a practice whose clients keep their therapist — the two outcomes are produced by the same work, which is covered in what buyers look for.

The corollary is uncomfortable. If a large share of the practice’s revenue is your caseload, then your clients face the transition that everyone worries about, because the clinician leaving is you. That is the same fact that discounts your valuation — see what is my therapy practice worth — appearing in its human form.

Records, and why the deal structure matters here

Clinical records are not an ordinary business asset, and how they are handled depends on how the transaction is built.

In a sale of the entity, the entity continues to exist and continues to hold what it held. In an asset sale, the entity is left behind — which raises questions about custody, access and continuity that have to be answered explicitly in the agreement rather than assumed. This is one of several reasons behavioral health deals are frequently pushed toward a sale of the company itself; the mechanics are in asset sale vs stock sale.

Do not work this out from a guide. Record custodianship, retention, access after closing and what clients must be told are governed by your licence, your state, your payer contracts and privacy law — not by the purchase agreement, and not by what is convenient. Get your own attorney and your own clinical consultant into this early, because it is a term of the deal and it is much harder to renegotiate afterwards.

Telling clients

Governed by your obligations rather than the deal timeline, and the sequencing question is genuinely hard.

Too early, and you create uncertainty during a process that may not complete — including for clients for whom uncertainty is clinically significant. Too late, and people who trusted you feel it was done to them.

What owners consistently report is that the clinical conversation and the commercial one need separating. Whether a particular client should be told, when, by whom and in what terms is a clinical judgement about that person, made with your consultant. It is not a communications workstream to be handed to the buyer’s marketing team, and a buyer who treats it as one is telling you something useful about the transition ahead.

Two things worth settling before you sign, not after:

Who says what, and when. Written into the agreement — including the buyer’s obligations on messaging and their restraint until you agree the moment.

What happens to clients who choose not to continue. Referral, transfer, records access. Plan it in advance rather than improvising during the busiest month of your professional life.

Your own transition is part of theirs

Most deals at this size include a period where you stay on. For clients who see you personally, that period is their transition, and how it is structured — months or years, tapering or abrupt, defined hours or open-ended — is negotiated back in the letter of intent, long before anyone thinks about it clinically.

Which is an argument for thinking about it clinically first. Work out what a responsible transition for your own clients actually requires, then negotiate a transition period that accommodates it. Doing this in the other order means discovering in month nine that you agreed to something that does not fit the people it applies to. Deal structure and what you actually receive covers how those obligations get set.

---

Nothing here is legal, clinical or ethical advice, and it is not a substitute for your board, your consultant or your attorney. Obligations differ by licence, state and payer, and they govern this regardless of what any deal document says.

If you are earlier than this and still working out whether the numbers justify the next two years, the valuation calculator is free and takes about four minutes.